Current market catalysts

8-K filing — Southern Cross Acquisition II Corp. (SCAT)

Filed: 2026-08-27 AccNo: 0001929980-26-000510 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Key Tronic shares are trading lower after the company reported a year-over-year decrease in Q4 sales results. The company announced it will not issue Q1 revenue and earnings guidance due to uncertainty in the timing of new program ramps and macroeconomic uncertainty.

8-K filing — GE Vernova Inc. (GEV)

Filed: 2026-08-27 AccNo: 0001996810-26-000153 Size: 144 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Gap Raises FY2026 Adj EPS Guidance from $2.30-$2.40 to $2.35-$2.45 vs $2.34 Est; Narrows FY2026 Sales Guidance from $15.520B-$15.670B to $15.554B-$15.631B vs $15.531B Est

Gap (NYSE:GAP) raises FY2026 Adj EPS guidance from $2.30-$2.40 to $2.35-$2.45 vs $2.34 analyst estimate. Narrows FY2026 sales outlook from $15.520 billion-$15.670 billion to $15.554 billion-$15.631 billion vs $15.531

Gap Inc. Names Michael Francis President & CEO Of Old Navy Effective Nov. 2

Gap Inc. (NYSE:GAP) today announced the appointment of Michael Francis as President and Chief Executive Officer of Old Navy, effective November 2, 2026. Francis will succeed Haio Barbeito, who will transition from his

Kazia Therapeutics shares are trading lower after the company announced a proposed public offering.

8-K filing — FIRST KEYSTONE CORP (FKYS)

Filed: 2026-08-27 AccNo: 0000737875-26-000031 Size: 156 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — DEVON ENERGY CORP/DE (DVN)

Filed: 2026-08-27 AccNo: 0001193125-26-371317 Size: 142 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

8-K filing — Worksport Ltd (WKSP)

Filed: 2026-08-27 AccNo: 0001493152-26-040401 Size: 470 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

8-K filing — Quanex Building Products CORP (NX)

Filed: 2026-08-27 AccNo: 0001171843-26-005764 Size: 213 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Gap Q2 Adj. EPS $0.52 Beats $0.48 Estimate, Sales $3.651B Miss $3.690B Estimate

Gap (NYSE:GAP) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.48 by 8.33 percent. This is a 8.77 percent decrease over earnings of $0.57 per share from the same period

Founder Group Announces 100-For-1 Share Combination, Effective September 1, 2026

Beginning with the opening of trading on September 1, 2026, the Company's Class A shares of no par value each (the "Class A Shares") will trade on the Nasdaq Capital Market on an adjusted basis, under the

LifeVantage Plans To Not Issue FY27 Outlook Due To Recent CEO Transition

LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced due to the recent transition in the Chief

iTonic Holdings Says CFO Zhixin Li Resigned Effective Immediately; Appoints Simin Tan As CFO

https://www.sec.gov/Archives/edgar/data/1970544/000121390026094376/ea0302677-6k_itonic.htm

8-K filing — Elastic N.V. (ESTC)

Filed: 2026-08-27 AccNo: 0001707753-26-000036 Size: 151 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

GE Vernova Announces Appointment Of Claire McDonough As CFO Effective January 1, 2027

https://www.gevernova.com/news/press-releases/ge-vernova-announces-chief-financial-officer-transition

8-K filing — Forte Biosciences, Inc. (FBRX)

Filed: 2026-08-27 AccNo: 0001140361-26-034698 Size: 302 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

$100 Invested In Lam Research 20 Years Ago Would Be Worth This Much Today

Lam Research (NASDAQ:LRCX) has outperformed the market over the past 20 years by 14.91% on an annualized basis producing an average annual return of 24.15%. Currently, Lam Research has a market capitalization of $398.65

8-K filing — STIFEL FINANCIAL CORP (SF-PD)

Filed: 2026-08-27 AccNo: 0001193125-26-371310 Size: 280 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

PagerDuty Raises FY2027 Adj EPS Guidance from $1.27-$1.32 to $1.33-$1.37 vs $1.32 Est; Raises FY2027 Sales Guidance from $488.500M-$496.500M to $491.500M-$496.500M vs $494.220M Est

PagerDuty (NYSE:PD) raises FY2027 Adj EPS guidance from $1.27-$1.32 to $1.33-$1.37 vs $1.32 analyst estimate. Raises FY2027 sales outlook from $488.500 million-$496.500 million to $491.500 million-$496.500 million vs

IM Cannabis Shares Start Trading On 30-For-1 Split Basis

IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, announces that, further to its press release dated August 18, 2026, the

8-K filing — WEYERHAEUSER CO (WY)

Filed: 2026-08-27 AccNo: 0000106535-26-000009 Size: 46 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — ChronoScale Holdings Corp (CHRN)

Filed: 2026-08-27 AccNo: 0001493152-26-040398 Size: 237 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Affirm Expands Its Global Partnership With Shopify To Launch Shop Pay Installments In Australia

Affirm expands its global partnership with Shopify to launch Shop Pay Installments in Australia. Powered exclusively by Affirm, it provides Australians the added flexibility to pay over time with no hidden fees, using

8-K filing — OceanLight Acquisition Corp (OCLTU)

Filed: 2026-08-27 AccNo: 0001829126-26-009426 Size: 414 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Skillsoft Corp. (SKIL)

Filed: 2026-08-27 AccNo: 0001437749-26-029105 Size: 154 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

8-K filing — Avidbank Holdings, Inc. (AVBH)

Filed: 2026-08-27 AccNo: 0001437749-26-029104 Size: 9 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K/A filing — WESTERN DIGITAL CORP (WDC)

Filed: 2026-08-27 AccNo: 0001193125-26-371309 Size: 167 KB Item 3.02: Unregistered Sales of Equity Securities

8-K filing — Life Time Group Holdings, Inc. (LTH)

Filed: 2026-08-27 AccNo: 0001869198-26-000049 Size: 134 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.